Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Abroad (travel likely)RecruitingPHASE1

Conditions

T-cell Lymphoma · Cutaneous/Peripheral T-Cell Lymphoma · Peripheral T-cell Lymphoma · Peripheral T-Cell Lymphoma, Not Classified · Primary Cutaneous T-cell Lymphoma · Cutaneous T-Cell Lymphoma, Unspecified · Cutaneous T-cell Lymphoma · Follicular T-Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Sézary's Disease · Mycosis Fungoides

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Mayo Clinic Arizona, Scottsdale, Arizona, United States

    Contact: Study coordinator (Breanna Keller)
    Contact: Principal Investigator (Aaron R Mangold, M.D.)
  • City of Hope Medical Foundation, Duarte, California, United States

    Contact: Study coordinator (Tracey Nguyen)
    Contact: Principal Investigator (Christiane Querfeld, M.D., Ph.D.)
  • University of Southern California, Los Angeles, California, United States

    Contact: Study coordinator (Christine Duran)
    Contact: Principal Investigator (Ann F Mohrbacher, M.D.)
  • University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

    Contact: Study coordinator (Rebecca Reed, MPH-PHP) · rebecca.reed@cuanschutz.edu · 303-724-4874
    Contact: Principal Investigator (Brad Haverkos, M.D.)
  • Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States

    Contact: Study coordinator (Benjamin Joslin, MPH, CCRC)
    Contact: Principal Investigator (Jonathan Moreira, M.D.)
  • University of Michigan, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Tina Jones)
    Contact: Principal Investigator (Ryan A Wilcox, MD, PhD)
  • Barbara Ann Karmanos Cancer Institute Wayne State University, Detroit, Michigan, United States

    Contact: Study coordinator (Erik Carr)
    Contact: Principal Investigator (Dipenkumar Modi, M.D.)
  • Columbia University, New York, New York, United States

    Contact: Study coordinator (Anxhela Kalia)
    Contact: Principal Investigator (Barbara Pro, M.D.)
  • University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Charity L Ruhl, LPN)
    Contact: Principal Investigator (Oleg E Akilov, M.D., Ph.D.)
  • The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Alda J Ashu, BSN, RN, OCN)
    Contact: Principal Investigator (Auris O Huen, MD, PharmD)
Study leads
  • Ali Moiin, MD

    Study Director

    SciTech Development, Inc.

  • Oleg E Akilov, MD, PhD

    Principal Investigator

    University of Pittsburgh Medical Center (UPMC)

  • Ann F Mohrbacher, MD

    Principal Investigator

    University of Southern California

  • Barbara Pro, MD

    Principal Investigator

    Columbia University

  • Dipenkumar Modi, MD

    Principal Investigator

    Barbara Ann Karmanos Cancer Institute

  • Auris O Huen, MD, PharmD

    Principal Investigator

    M.D. Anderson Cancer Center

  • Ryan A Wilcox, MD, PhD

    Principal Investigator

    University of Michigan

  • Brad Haverkos, M.D.

    Principal Investigator

    University of Colorado, Denver

  • Christiane Querfeld, M.D., Ph.D.

    Principal Investigator

    City of Hope Medical Foundation

  • Aaron R Mangold, M.D.

    Principal Investigator

    Mayo Clinic

  • Jonathan Moreira, M.D.

    Study Director

    Northwestern University, Robert H. Lurie Comprehensive Cancer Center